RU2007118687A - Триазолы, используемые в качестве ингибиторов протеинкиназ - Google Patents
Триазолы, используемые в качестве ингибиторов протеинкиназ Download PDFInfo
- Publication number
- RU2007118687A RU2007118687A RU2007118687/04A RU2007118687A RU2007118687A RU 2007118687 A RU2007118687 A RU 2007118687A RU 2007118687/04 A RU2007118687/04 A RU 2007118687/04A RU 2007118687 A RU2007118687 A RU 2007118687A RU 2007118687 A RU2007118687 A RU 2007118687A
- Authority
- RU
- Russia
- Prior art keywords
- aliphatic group
- optionally substituted
- group
- treating
- agent
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims 34
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 208000020084 Bone disease Diseases 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000001301 oxygen Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- -1 1,2-methylenedioxy Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 229940124622 immune-modulator drug Drugs 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 239000003076 neurotropic agent Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
Claims (17)
1. Соединение формулы (I)
где X обозначает CH или N;
Y обозначает CH2, NH, NR, O или S;
R1 обозначает водород или C1-6алкил;
R2 обозначает водород;
R3 обозначает необязательно замещенную 6-членную моноциклическую арильную группу, содержащую от 0 до 3 гетероатомов, независимо выбранных из азота, кислорода или серы;
R5 обозначает водород, -C1-6алифатическую группу, -CN, -OH, -O(C1-6алифатическую группу), -CO2H, -CO2(C1-6алифатическую группу), -CON(R)2, -O(галогенC1-4алифатическую группу), -галогенC1-4алифатическую группу, -NO2, -галоген, -NR°2 или -C1-6алифатическую группу, необязательно замещенную NH2;
R4 обозначает водород, галоген; -R°; -OR°; -SR°; 1,2-метилендиокси; 1,2-этилендиокси; фенил (Ph), необязательно замещенный R°; -O(Ph), необязательно замещенный R°; -(CH2)1-2(Ph), необязательно замещенный R°; -CH=CH(Ph), необязательно замещенный R°; -NO2; -CN; -N(R°)2; -NR°C(O)R°; -NR°C(S)R°; -NR°C(О)N(R°)2; -NR°C(S)N(R°)2; -NR°CO2R°; -NR°NR°C(O)R°; -NR°NR°C(О)N(R°)2; -NR°NR°CO2R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -CO2R°; -C(O)R°; -C(S)R°; -C(О)N(R°)2; -C(S)N(R°)2; -C(=NH)-N(R°)2, -OC(O)N(R°)2; -OC(O)R°; -C(O)N(OR°)R°; -C(NOR°)R°; -S(O)2R°; -S(O)3R°; -SO2N(R°)2; -S(O)R°; -NR°SO2N(R°)2; -NR°SO2R°; -N(OR°)R°; -C(=NH)-N(R°)2; -(CH2)0-2NHC(O)R°, =О, =S, =NNHR*, =NN(R*)2, =NNHC(O)R*, =NNHCO2(алкил), =NNHSO2(алкил) или =NR*, где
каждый R° независимо выбран из водорода, необязательно замещенной C1-6алифатической группы, незамещенной 5-6-членной гетероарильной или гетероциклической группы, фенила, -O(Ph) или -CH2(Ph), или, независимо от приведенного выше определения, два независимо выбранных R°, присутствующие в составе одного заместителя или разных заместителей, вместе с атомом (атомами), к которому присоединена группа R°, образуют 5-8-членную гетероциклическую, арильную или гетероарильную группу или 3-8-членную циклоалкильную группу, содержащую от 0 до 3 гетероатомов, независимо выбранных из азота, кислорода или серы;
алифатическая группа R° необязательно замещена NH2, NH(C1-4алифатической группой), N(C1-4алифатической группой)2, галогеном, C1-4алифатической группой, OH, О(C1-4алифатической группой), NO2, CN, CO2H, CO2(C1-4алифатической группой), O(галогенC1-4алифатической группой) или галоген(C1-4алифатической группой), где каждая из вышеуказанных C1-4алифатических групп является незамещенной;
каждый R* независимо выбран из водорода или C1-6алифатической группы, необязательно замещенной NH2, NH(C1-4алифатической группой), N(C1-4алифатической группой)2, галогеном, C1-4алифатической группой, OH, О(C1-4алифатической группой), NO2, CN, CO2H, CO2(C1-4алифатической группой), O(галогенC1-4алифатической группой) или галоген(C1-4алифатической группой), где каждая из вышеуказанных C1-4алифатических групп является незамещенной; и
R обозначает водород или C1-6алифатическую группу, необязательно замещенную =O, =S, -NH2, NH(C1-4алифатической группой), N(C1-4алифатической группой)2, галогеном, C1-4алифатической группой, OH, О(C1-4алифатической группой), NO2, CN, CO2H, CO2(C1-4алифатической группой), O(галогенC1-4алифатической группой) или галоген(C1-4алифатической группой), где каждая из вышеуказанных C1-4алифатических групп является незамещенной;
где каждый необязательный заместитель указанной арильной группы независимо выбирают из группы, включающей в себя галоген; -R°; -OR°; -SR°; фенил (Ph), необязательно замещенный R°; -O(Ph), необязательно замещенный R°; -(CH2)1-2(Ph), необязательно замещенный R°; -CH=CH(Ph), необязательно замещенный R°; -NO2; -CN; -N(R°)2; -NR°C(O)R°; -NR°C(S)R°; -NR°C(O)N(R°)2; -NR°C(S)N(R°)2; -NR°CO2R°; -NR°NR°C(O)R°; -NR°NR°C(O)N(R°)2; -NR°NR°CO2R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -CO2R°; -C(O)R°; -C(S)R°; -C(O)N(R°)2; -C(S)N(R°)2; -OC(О)N(R°)2; -OC(O)R°; -C(O)N(OR°)R°; -C(NOR°)R°; -S(O)2R°; -S(O)3R°; -SO2N(R°)2; -S(O)R°; -NR°SO2N(R°)2; -NR°SO2R°; -N(OR°)R°; -C(=NH)-N(R°)2; -P(O)2R°; -PO(R°)2; -OPO(R°)2; -(CH2)0-2NHC(O)R°; фенил (Ph), необязательно замещенный R°; -O(Ph), необязательно замещенный R°; -(CH2)1-2(Ph), необязательно замещенный R°; независимо от приведенного выше определения, два независимо выбранных R°, присутствующих в составе одного заместителя или разных заместителей, вместе с атомом (атомами), к которому присоединена группа R°, образуют 3-12-членный насыщенный, частично ненасыщенный или полностью ненасыщенный моноциклический или бициклический фрагмент, содержащий от 0 до 4 гетероатомов, независимо выбранных из азота, кислорода или серы, и необязательно замещенный R.
2. Соединение по п. 1, где R1 обозначает водород.
3. Соединение по п. 1, где X обозначает N.
4. Соединение по п. 1, где Y обозначает O.
5. Соединение по п. 1, где Y обозначает NR.
6. Соединение по п.1, где R3 обозначает 6-членную гетероарильную группу, содержащую 1 или 2 гетероатома азота.
7. Соединение по п.1, где R3 обозначает 2-пиридил.
8. Соединение по любому из пп. 1-7, где R5 обозначает -CN или H.
9. Соединение по п.1, имеющее формулу (I-b) или (I-c):
10. Соединение по п.1, где указанное соединение выбрано из группы, состоящей из:
11. Соединение по п.1, где указанное соединение выбрано из группы, состоящей из
12. Соединение по п. 1, которое выбрано из группы, состоящей из
13. Фармацевтическая композиция, содержащая
соединение по любому из пп. 1-7 и 9-12 или его фармацевтически приемлемую соль,
и фармацевтически приемлемые носитель, вспомогательное средство или наполнитель.
14. Композиция по п.13, дополнительно содержащая другое терапевтическое средство, выбранное из химиотерапевтического или антипролиферативного средства, средства для лечения болезни Альцгеймера, средства для лечения болезни Паркинсона, средства для лечения рассеянного склероза (MS), средства для лечения астмы, средства для лечения шизофрении, противовоспалительного средства, иммуномодулирующего или иммунодепрессивного средства, нейротропного фактора, средства для лечения сердечно-сосудистого заболевания, средства для лечения деструктивных заболеваний костей, средства для лечения болезни печени, средства для лечения болезни крови или средства для лечения иммунодефицитного состояния.
15. Способ ингибирования киназной активности FLT-3 или c-KIT протеинкиназ в биологическом образце, включающий стадию
приведения в контакт указанного биологического образца с
a) композицией по п.13 или
b) соединением по любому из пп. 1-7 или 9-12 или его фармацевтически приемлемой солью.
16. Применение соединения по пп. 1-7 и 9-12 для получения лекарственного средства для лечения или уменьшения тяжести заболевания или состояния, выбранного из аллергических расстройств, пролиферативных расстройств, аутоиммунных расстройств, состояний, связанных с трансплантацией органов, воспалительных расстройств, расстройств, опосредованных иммунной системой, или деструктивных костных расстройств.
17. Применение по п.16, где указанная композиция дополнительно содержит другое терапевтическое средство, выбранное из химиотерапевтического или антипролиферативного средства, средства для лечения болезни Альцгеймера, средства для лечения болезни Паркинсона, средства для лечения рассеянного склероза (MS), средства для лечения астмы, средства для лечения шизофрении, противовоспалительного средства, иммуномодулирующего или иммунодепрессивного средства, нейротропного фактора, средства для лечения сердечно-сосудистого заболевания, средства для лечения деструктивных заболеваний костей, средства для лечения болезни печени, средства для лечения болезни крови или средства для лечения иммунодефицитного состояния.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62127004P | 2004-10-21 | 2004-10-21 | |
| US60/621,270 | 2004-10-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007118687A true RU2007118687A (ru) | 2008-11-27 |
| RU2393155C2 RU2393155C2 (ru) | 2010-06-27 |
Family
ID=35809788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007118687/04A RU2393155C2 (ru) | 2004-10-21 | 2005-10-21 | Триазолы, используемые в качестве ингибиторов протеинкиназ |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7645775B2 (ru) |
| EP (1) | EP1811998B1 (ru) |
| JP (1) | JP5085330B2 (ru) |
| KR (1) | KR20070085407A (ru) |
| CN (1) | CN101072556A (ru) |
| AR (1) | AR054088A1 (ru) |
| AT (1) | ATE485042T1 (ru) |
| AU (1) | AU2005299816B2 (ru) |
| BR (1) | BRPI0517435A (ru) |
| CA (1) | CA2584752A1 (ru) |
| CY (1) | CY1111197T1 (ru) |
| DE (1) | DE602005024293D1 (ru) |
| DK (1) | DK1811998T3 (ru) |
| ES (1) | ES2352453T3 (ru) |
| HR (1) | HRP20100715T1 (ru) |
| IL (1) | IL182664A0 (ru) |
| MX (1) | MX2007004841A (ru) |
| NO (1) | NO20072567L (ru) |
| NZ (1) | NZ555088A (ru) |
| PL (1) | PL1811998T3 (ru) |
| PT (1) | PT1811998E (ru) |
| RU (1) | RU2393155C2 (ru) |
| SI (1) | SI1811998T1 (ru) |
| TW (1) | TW200630090A (ru) |
| WO (1) | WO2006047256A1 (ru) |
| ZA (1) | ZA200703950B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2474579C2 (ru) * | 2007-10-18 | 2013-02-10 | Янссен Фармацевтика Нв | Тризамещенные 1,2,4-триазолы |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100298557A1 (en) | 2006-12-28 | 2010-11-25 | Taisho Pharmaceutical Co., Ltd | Pyrazolopyrimidine compound |
| US7872000B2 (en) | 2006-12-29 | 2011-01-18 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors |
| ES2672172T3 (es) | 2006-12-29 | 2018-06-12 | Rigel Pharmaceuticals, Inc. | Triazoles N3-heteroarilsustituidos y triazoles N5-heteroarilsustituidos útiles como inhibidores de Axl |
| PT2114955E (pt) | 2006-12-29 | 2013-04-18 | Rigel Pharmaceuticals Inc | Triazoles substituídos com arilo bicíclico em ponte ou heteroarilo bicíclico em ponte úteis como inibidores de axl |
| WO2008083356A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| AU2014200824B2 (en) * | 2006-12-29 | 2016-12-15 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as Axl inhibitors |
| AU2016259396B2 (en) * | 2006-12-29 | 2018-11-08 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as Axl inhibitors |
| JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| ES2442932T3 (es) | 2008-03-19 | 2014-02-14 | Janssen Pharmaceutica N.V. | 1,2,4-Triazoles trisustituidos como moduladores de receptores nicotínicos de acetilcolina |
| CL2009001125A1 (es) | 2008-05-09 | 2011-02-11 | Janssen Pharmaceutica Nv | Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. |
| CA2730251C (en) | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2387572B1 (en) * | 2009-01-15 | 2015-09-16 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CA2749843C (en) | 2009-01-16 | 2017-09-05 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| EP2569280B1 (en) * | 2010-05-11 | 2015-02-25 | Sanofi | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
| TW201206910A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof |
| JP2013526529A (ja) | 2010-05-11 | 2013-06-24 | サノフイ | 置換されたｎ−ヘテロアリールビピロリジンカルボキサミド、その製造及び治療上の使用 |
| EP2569305B1 (en) | 2010-05-11 | 2015-04-08 | Sanofi | Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| EP2569303A1 (en) | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| JP5833105B2 (ja) | 2010-05-11 | 2015-12-16 | サノフイ | 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用 |
| CN102787094B (zh) * | 2011-05-17 | 2015-09-23 | 李晖 | 培养基、细胞培养用试剂盒及细胞培养方法 |
| US9540345B2 (en) | 2013-03-05 | 2017-01-10 | Hoffmann-La Roche Inc. | Antiviral compounds |
| EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| MX2021015572A (es) * | 2019-06-28 | 2022-04-06 | Shanghai Pharmaceuticals Holding Co Ltd | Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637592A (en) * | 1994-07-12 | 1997-06-10 | Janssen Pharmaceutica N.V. | Acyl derivatives of azolones |
| CN1100777C (zh) * | 1997-02-19 | 2003-02-05 | 伯莱克斯实验室公司 | 作为nos抑制剂的n－杂环衍生物 |
| RU2340611C2 (ru) * | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
| CN100357278C (zh) | 2000-12-22 | 2007-12-26 | 奥索-麦克尼尔药品公司 | 作为激酶抑制剂的取代的三唑二胺衍生物 |
| DE10123586A1 (de) | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| DE602004025258D1 (de) * | 2003-08-06 | 2010-03-11 | Vertex Pharma | Aminotriazol-verbindungen als proteinkinase-hemmer |
-
2005
- 2005-10-21 DE DE602005024293T patent/DE602005024293D1/de not_active Expired - Lifetime
- 2005-10-21 HR HR20100715T patent/HRP20100715T1/hr unknown
- 2005-10-21 ZA ZA200703950A patent/ZA200703950B/en unknown
- 2005-10-21 WO PCT/US2005/037830 patent/WO2006047256A1/en not_active Ceased
- 2005-10-21 CA CA002584752A patent/CA2584752A1/en not_active Abandoned
- 2005-10-21 TW TW094137050A patent/TW200630090A/zh unknown
- 2005-10-21 NZ NZ555088A patent/NZ555088A/en not_active IP Right Cessation
- 2005-10-21 US US11/255,569 patent/US7645775B2/en not_active Expired - Fee Related
- 2005-10-21 AU AU2005299816A patent/AU2005299816B2/en not_active Ceased
- 2005-10-21 PT PT05815914T patent/PT1811998E/pt unknown
- 2005-10-21 KR KR1020077011405A patent/KR20070085407A/ko not_active Withdrawn
- 2005-10-21 AR ARP050104417A patent/AR054088A1/es not_active Application Discontinuation
- 2005-10-21 AT AT05815914T patent/ATE485042T1/de active
- 2005-10-21 JP JP2007538052A patent/JP5085330B2/ja not_active Expired - Fee Related
- 2005-10-21 CN CNA2005800420882A patent/CN101072556A/zh active Pending
- 2005-10-21 SI SI200531181T patent/SI1811998T1/sl unknown
- 2005-10-21 ES ES05815914T patent/ES2352453T3/es not_active Expired - Lifetime
- 2005-10-21 BR BRPI0517435-0A patent/BRPI0517435A/pt not_active IP Right Cessation
- 2005-10-21 EP EP05815914A patent/EP1811998B1/en not_active Expired - Lifetime
- 2005-10-21 DK DK05815914.6T patent/DK1811998T3/da active
- 2005-10-21 RU RU2007118687/04A patent/RU2393155C2/ru not_active IP Right Cessation
- 2005-10-21 MX MX2007004841A patent/MX2007004841A/es unknown
- 2005-10-21 PL PL05815914T patent/PL1811998T3/pl unknown
-
2007
- 2007-04-19 IL IL182664A patent/IL182664A0/en unknown
- 2007-05-21 NO NO20072567A patent/NO20072567L/no not_active Application Discontinuation
-
2011
- 2011-01-04 CY CY20111100005T patent/CY1111197T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2474579C2 (ru) * | 2007-10-18 | 2013-02-10 | Янссен Фармацевтика Нв | Тризамещенные 1,2,4-триазолы |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE485042T1 (de) | 2010-11-15 |
| PL1811998T3 (pl) | 2011-05-31 |
| NO20072567L (no) | 2007-07-17 |
| CN101072556A (zh) | 2007-11-14 |
| DK1811998T3 (da) | 2011-02-14 |
| DE602005024293D1 (de) | 2010-12-02 |
| ES2352453T3 (es) | 2011-02-18 |
| AU2005299816B2 (en) | 2011-09-01 |
| JP5085330B2 (ja) | 2012-11-28 |
| KR20070085407A (ko) | 2007-08-27 |
| US7645775B2 (en) | 2010-01-12 |
| MX2007004841A (es) | 2007-05-21 |
| PT1811998E (pt) | 2010-12-23 |
| TW200630090A (en) | 2006-09-01 |
| CY1111197T1 (el) | 2015-06-11 |
| IL182664A0 (en) | 2007-09-20 |
| CA2584752A1 (en) | 2006-05-04 |
| AU2005299816A2 (en) | 2006-05-04 |
| EP1811998B1 (en) | 2010-10-20 |
| HRP20100715T1 (hr) | 2011-02-28 |
| AR054088A1 (es) | 2007-06-06 |
| US20070270410A1 (en) | 2007-11-22 |
| ZA200703950B (en) | 2008-07-30 |
| JP2008517923A (ja) | 2008-05-29 |
| NZ555088A (en) | 2009-08-28 |
| SI1811998T1 (sl) | 2011-01-31 |
| EP1811998A1 (en) | 2007-08-01 |
| AU2005299816A1 (en) | 2006-05-04 |
| WO2006047256A1 (en) | 2006-05-04 |
| RU2393155C2 (ru) | 2010-06-27 |
| BRPI0517435A (pt) | 2008-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007118687A (ru) | Триазолы, используемые в качестве ингибиторов протеинкиназ | |
| ES2655899T3 (es) | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de la Trk cinasa | |
| JP2008517923A5 (ru) | ||
| RU2296124C2 (ru) | Производные 2-аминоникотинамида и их применение в качестве ингибиторов vegf-рецептора тирозинкиназы | |
| EP1626714B1 (en) | Diaryl ureas for diseases mediated by pdgfr | |
| RU2650895C2 (ru) | Соединения замещенных пиразолонов и способы использования | |
| JP2004509114A5 (ru) | ||
| CA2817460A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| SK5912003A3 (en) | Novel pyridine-substituted pyrazolopyridine derivatives | |
| RS51548B (sr) | Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaza | |
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| ME02409B (me) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| CA2422299A1 (en) | Triazole compounds useful as protein kinase inhibitors | |
| KR20180094976A (ko) | Tank-결합 키나제 억제제 화합물 | |
| JP2004509113A5 (ru) | ||
| JP2004509117A5 (ru) | ||
| AU2015365465A1 (en) | Amido thiadiazole derivatives as NADPH Oxidase inhibitors | |
| JP2020517595A (ja) | サイクリン依存性キナーゼｃｄｋ９の新規阻害剤 | |
| AU2019346028A1 (en) | Novel compounds as NADPH Oxidase inhibitors | |
| KR20070027723A (ko) | 4,6-이치환된 피리미딘 및 단백질 키나제 억제제로서의이의 용도 | |
| JP7763538B2 (ja) | Ｐａｒｐ７阻害剤及びその使用 | |
| JP2005504795A5 (ru) | ||
| AR023292A1 (es) | Un compuesto derivado de imidazol, un procedimiento para su preparacion, y un medicamento y una composicion farmaceutica que comprende a dicho compuesto | |
| KR101133943B1 (ko) | 허혈성 심장질환의 세포 치료에 사용되는 ｅＮＯＳ 전사강화제 | |
| JPWO2022060973A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20121022 |